Alpha 2.0
Login Register
» Articles » PMID: 36581076

No Association Between Dupilumab Use and Short-term Cancer Development in Atopic Dermatitis Patients

Overview
Journal J Allergy Clin Immunol Pract
Specialty Allergy & Immunology
Date 2022 Dec 29
PMID 36581076
Authors
Shayan Owji
Benjamin Ungar
Danielle P Dubin
Dina Poplausky
Jade N Young
Sabrina Ghalili
Joseph Han
Dhipthika Srinivasan
Sarah Packer
Ana B Pavel
Joel Correa Da Rosa
Emma Guttman-Yassky
Nicholas Gulati
Affiliations
Soon will be listed here.
Citing Articles

Is the Increase in Tumour Markers and Hashimoto's Thyroiditis an Incidental Event During Dupilumab Treatment? A Case Report.

Lin K, Shen W, Lin N, Li S, Wu L Acta Derm Venereol. 2025; 105:adv41250.

PMID: 39907509 PMC: 11877854. DOI: 10.2340/actadv.v105.41250.

Effectiveness and Safety of Dupilumab and Tralokinumab for Treating Atopic Dermatitis and Pruritic Skin Disorders in Oncological Patients: A Narrative Review.

Lauletta G, Potestio L, Patruno C, DE Lucia M, Napolitano M Clin Cosmet Investig Dermatol. 2025; 18:311-317.

PMID: 39901963 PMC: 11789671. DOI: 10.2147/CCID.S511559.

The role of dupilumab in the treatment of eosinophilic esophagitis.

Syverson E, Rubinstein E, Lee J, McDonald D, Hait E Immunotherapy. 2024; 16(13):845-852.

PMID: 39073081 PMC: 11457672. DOI: 10.1080/1750743X.2024.2377060.

Biologics and small molecules treatment for moderate-to-severe atopic dermatitis patients with comorbid conditions and special populations: an Italian perspective.

Guglielmo A, Deotto M, Naldi L, Stinco G, Pileri A, Piraccini B Dermatol Reports. 2024; 16(2):9839.

PMID: 38957642 PMC: 11216152. DOI: 10.4081/dr.2023.9839.

Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review.

Mansilla-Polo M, Morgado-Carrasco D Dermatol Ther (Heidelb). 2024; 14(6):1389-1442.

PMID: 38763966 PMC: 11169156. DOI: 10.1007/s13555-024-01166-4.